<DOC>
	<DOCNO>NCT00004784</DOCNO>
	<brief_summary>OBJECTIVES : I . Compare effect ursodiol ( ursodeoxycholic acid ) , without methotrexate , pruritus , incapacitation index , serum marker activity severity patient primary biliary cirrhosis . II . Compare effect regimens development ascites , encephalopathy , varix ( bleed pre-existing varix ) , histologic liver change , transplantation , survival . III . Compare toxicity safety regimen .</brief_summary>
	<brief_title>Phase III Randomized Study Ursodiol With Vs Without Methotrexate Primary Biliary Cirrhosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients stratify participate institution Ludwig histologic stage . All patient treat ursodiol ( ursodeoxycholic acid , UDCA ) 6 month . If entry criterion continue meet , patient randomly assign UDCA/methotrexate UDCA/placebo . Combination therapy continue least 5 year .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics The follow criterion must meet prior study entry ursodiol treatment : Bilirubin le 3 mg/dL Alkaline phosphatase least 1.5 time normal limit Albumin least 3 g/dL The following criterion must meet prior randomization Arms I II : Primary biliary cirrhosis ( PBC ) , i.e . : Cholestatic liver disease least 6 month prior randomization Liver biopsy compatible PBC within 6 month prior randomization No biliary obstruction ultrasound , computerized tomography , cholangiography The following exclude : Asymptomatic stage I liver histology ( Ludwig classification ) Hepatic encephalopathy Ascites Variceal bleed No liver disease etiology , e.g . : Chronic hepatitis B C Autoimmune chronic active hepatitis Alcoholic liver disease Sclerosing cholangitis Druginduced liver disease Symptomatic obstructive gallstone Prior/Concurrent Therapy At least 6 month since follow immunosuppressive : Cyclosporine Tacrolimus Methotrexate At least 3 month since immunosuppressive , e.g . : Azathioprine Chlorambucil Colchicine Corticosteroids Penicillamine At least 3 month since rifampin Patient Characteristics Life expectancy : No major illness limit life span Hematopoietic : WBC least 2500/mm3 Absolute granulocyte count least 1500/mm3 Platelet count least 80,000/mm3 Hepatic : See Disease Characteristics Renal : Creatinine clearance least 60 mL/min Pulmonary : No diffusion capacity vital capacity le 50 % predict Other : Antimitochondrial antibody positive HIV antibody negative No alcoholism within past 2 year No epilepsy require phenytoin No malignancy within past 5 year skin cancer No pregnant woman Adequate contraception require fertile patient</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>cirrhosis</keyword>
	<keyword>gastrointestinal disorder</keyword>
	<keyword>primary biliary cirrhosis</keyword>
	<keyword>rare disease</keyword>
</DOC>